Diclofenac transdermal second generation - Crescita Therapeutics

Drug Profile

Diclofenac transdermal second generation - Crescita Therapeutics

Alternative Names: Diclofenac sodium topical solution 2% w/w; MNK-395; NRI-1004; Pennsaid 2%; Pennsaid Gel; Pennsaid Plus; Pennsaid Viscous Solution

Latest Information Update: 21 Nov 2016

Price : $50

At a glance

  • Originator Nuvo Research
  • Developer Horizon Pharma; NovaMedica; Nuvo Research
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Musculoskeletal pain

Most Recent Events

  • 01 Nov 2016 Nuvo Pharmaceuticals initiates enrolment in a phase III trial for Musculoskeletal pain in Germany
  • 17 Oct 2016 The German Federal Institute for Drugs and Medical Devices and Ethical Review Committee granted approval for a phase III study in Musculoskeletal pain
  • 13 Jul 2016 Nuvo Research plans a phase III trial for Musculoskeletal pain in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top